5-Aminosalicylates in inflammatory bowel disease: choosing the right dose (Q34351009)

1 August 2017

1 reference

title

5-Aminosalicylates in inflammatory bowel disease: choosing the right dose (English)

1 reference

inflammatory bowel diseases

1 August 2017

main subject

0 references

author name string

Qasim A

series ordinal

1

1 reference

1 August 2017

Seery J

series ordinal

2

1 reference

1 August 2017

O'Morain CA

series ordinal

3

1 reference

1 August 2017

language of work or name

1 reference

1 June 2001

1 reference

Digestive and Liver Disease

1 August 2017

published in

1 reference

1 August 2017

volume

33

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

393-398

1 reference

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

5-aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

An oral preparation to release drugs in the human colon

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

pH-profile and regional transit times of the normal gut measured by a radiotelemetry device

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Gastrointestinal pH profiles in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Optimum dose of olsalazine for maintaining remission in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Second trial of mesalamine therapy in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

5-Aminosalicylates for prevention of recurrence in patients with Crohn's disease: time for a reappraisal?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980008-6

7 January 2021

10.1016/S1590-8658(01)80008-6

Identifiers

DOI

1 reference

1 August 2017

1 reference